NICE draft RA recommendations leave "little hope for patients"
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, today published draft recommendations saying that rheumatoid arthritis (RA) patients should only be prescribed a second TNF-inhibitor as part of clinical research.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.